Temporary Covered Metallic Ureteral Stent Placement for Ureteral Strictures following Kidney Transplantation: Experience in 8 Patients

2020 ◽  
Vol 31 (11) ◽  
pp. 1795-1800
Author(s):  
Chuanwu Cao ◽  
Jong-Woo Kim ◽  
Ji Hoon Shin ◽  
Maoqian Li ◽  
Bumsik Hong ◽  
...  
2016 ◽  
Vol 30 (2) ◽  
pp. 153-161 ◽  
Author(s):  
Joseph G. Maliakkal ◽  
Daniel C. Brennan ◽  
Charles Goss ◽  
Timothy A. Horwedel ◽  
Howard Chen ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Faris Hashim ◽  
Shehzad Rehman ◽  
Jon A. Gregg ◽  
Vikas R. Dharnidharka

The placement of ureteral stent (UrSt) at kidney transplantation reduces major urological complications but increases the risk for developing nephropathy from the BK virus. It is unclear whether UrSt placement increases nephropathy risk by increasing risk of precursor viral replication or by other mechanisms. We retrospectively investigated whether UrSt placement increased the risk for developing BK Viremia (BKVM) in adult and pediatric kidney transplants performed at the University of Florida between July 1, 2007, and December 31, 2010. In this period all recipients underwent prospective BKV PCR monitoring and were maintained on similar immunosuppression. Stent placement or not was based on surgeon preference. In 621 transplants, UrSt were placed in 295 (47.5%). BKVM was seen in 22% versus 16% without UrSt (P=0.05). In multivariate analyses, adjusting for multiple transplant covariates, only UrSt placement remained significantly associated with BKVM (P=0.04). UrSt placement significantly increased the risk for BKVM. Routine UrSt placement needs to be revaluated, since benefits may be negated by the need for more BK PCR testing and potential for graft survival-affecting nephritis.


2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S830-S830
Author(s):  
Harry Ross Powers ◽  
Walter Hellinger ◽  
Cherise Cortese ◽  
Mohamed Elrefaei ◽  
Samir Khouzam ◽  
...  

Abstract Background Histologic acute graft pyelonephritis (HAGPN) is a complication of kidney transplantation (KT) diagnosed serendipitously by renal biopsy. A retrospective review of 1391 patients who underwent KT at our institution between 2008 and 2017 identified 46 cases (cumulative incidence 5%). Rejection was present in 50% of biopsies demonstrating HAGPN, complicating management. The aims of this study were to identify risk factors and outcomes of HAGPN. Methods Recipient, donor, operative and post-transplant characteristics of 46 cases of HAGPN and 138 controls randomly selected from the 1345 patients who underwent KT between 2008 and 2017 were assessed in univariable and multivariable Cox regression models. Associations of HAGPN with death or graft failure were assessed in univariable models. Results In univariable analysis, characteristics associated with increased risk of HAGPN in order of decreasing hazard ratio (HR) were rejection (HR 10.82, 5.66-20.72), urinary tract infections (UTI) or asymptomatic bacteriuria (ASB) (HR 6.28, 3.43-11.50), urologic malfunction (UM) within 30 days of KT, (HR 5.34, 2.85-10.02), less than 4 matches at HLA A/B/DR loci (HR 3.74, 1.19-11.76), delayed graft function (DGF) (HR 2.1, 1.47-3.00), basiliximab induction (HR 1.59, 1.05-2.42), diabetes mellitus (DM) at KT (HR 1.52, 1.07-2.16), operative time (HR 1.11, 1.03-1.19) and cold ischemic time (CIT) (HR 1.05, 1.02-1.06). UM, rejection and UTI or ASB were the most significant risk factors based on clinical and statistical importance, and after adjusting for them, DM, transplant type, CIT, ureteral stent placement and DGF remained significant risk factors. In univariable analysis, ureteral stent placement at transplant (HR 0.60, 0.43-0.88) and living-related donor (HR 0.18, 0.04-0.78) were each associated with reduced risk of HAGPN which persisted after multivariable analysis. In univariable analysis, HAGPN was associated with death (HR 17.04, 7.93-39.31) and graft failure (HR 3.77, 1.73, 8.20). Conclusion HAGPN is an infrequent, unanticipated, clinically significant complication of renal transplantation. Post-transplant dysfunction of the allograft collection system may be a modifiable risk factor. Disclosures All Authors: No reported disclosures


2011 ◽  
Vol 22 (7) ◽  
pp. 1012-1016 ◽  
Author(s):  
Hung-Chieh Chen ◽  
Shu-Huei Shen ◽  
Jia-Hwia Wang ◽  
William J.S. Huang ◽  
Hsiou-Shan Tseng ◽  
...  

2010 ◽  
Vol 24 (10) ◽  
pp. 1571-1574 ◽  
Author(s):  
Davis P. Viprakasit ◽  
Hernan O. Altamar ◽  
Nicole L. Miller ◽  
S. Duke Herrell

2018 ◽  
Vol 252 (6) ◽  
pp. 721-731 ◽  
Author(s):  
Philippa R. Pavia ◽  
Allyson C. Berent ◽  
Chick W. Weisse ◽  
Dana Neiman ◽  
Kenneth Lamb ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document